Biotechnology - Asia-Pacific, Cardio-vascular

Filter

Popular Filters

Pharming and SIPI collaboration includes Ruconest marketing in China

02-07-2013

Dutch biotech company Pharming Group (NYSE Euronext: PHARM) and Shanghai Institute of Pharmaceutical…

Asia-PacificBiotechnologyCardio-vascularLicensingPharmaceuticalPharmingResearchRuconestSinopharm Group

Amgen and Cytokinetics expand omecamtiv mecarbil accord

12-06-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech company, has expanded its strategic…

AmgenAsia-PacificBiotechnologyCardio-vascularCytokineticsLicensingomecamtiv mecarbil

Amgen and Astellas link up on drugs for unmet medical needs in Japan

29-05-2013

World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

Amgen's Aranesp fails in heart patients; to invest $200 million in Singapore

18-01-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, announced top-line results…

AmgenAranespAsia-PacificBiotechnologyCardio-vascularProductionResearch

Shin Poong and LFB set up joint venture to manufacture biotech products

11-01-2013

South Korean drugmaker Shin Poong Pharmaceutical (KOSPI: 019170) and France's Laboratoire francais du…

Asia-PacificAtrynBiotechnologyCardio-vascularFVIIaLaboratoire francais du Fractionnement et desMergers & AcquisitionsProductionShin Poong Pharmaceutical

J&J's Janssen files Xarelto with FDA for new indication; buys Chinese firm

03-05-2012

US health care major Johnson & Johnson's (NYSE: JNJ) subsidiary Janssen Research & Development says it…

Asia-PacificBayerBioseal BiotechBiotechnologyCardio-vascularJanssenJohnson & JohnsonMergers & AcquisitionsNorth AmericaPharmaceuticalRegulationXarelto

Back to top